Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hematopoietic stem cell transplantation as rescue therapy for refractory autoimmune retinopathy: a case report.
Front Immunol
January 2025
Department of Ophthalmology, National University Hospital, National University Health System, Singapore, Singapore.
Autoimmune retinopathy (AIR) is a rare, potentially blinding retinal disease that remains a challenging condition to manage when resistant to conventional immune-modulatory approaches. We report clinical and electrophysiological improvement in a 49-year-old patient who underwent an autologous hematopoietic stem cell transplant (aHSCT) for thymoma-associated AIR after experiencing progressive disease despite receiving periocular and systemic steroids, mycophenolate mofetil, baricitinib, tacrolimus, bortezomib, rituximab, plasmapheresis, and intravenous immunoglobulin. The aHSCT had two stages: (i) peripheral blood stem cell harvest following mobilization with cyclophosphamide and granulocyte colony-stimulating factor, and (ii) conditioning regimen with plasmapheresis, rituximab, cyclophosphamide, and anti-thymocyte globulin high-dose therapy, followed by autologous hematopoietic cell infusion of 5.
View Article and Find Full Text PDFPrecision Assessment of Anti-NMDA Receptor Encephalitis: A Case Report on Integrating Clinical Course, Immunophenotyping, and Comprehensive Symptomatology in a Pediatric Patient With Adjunctive Hydrogen Therapy.
In Vivo
December 2024
Rheumatology/Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.;
Background/aim: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, though rare, is the most common form of autoimmune encephalitis, predominantly affecting young individuals, particularly females. Standard treatments include corticosteroids, intravenous immunoglobulins (IVIG), and plasmapheresis, with rituximab recommended for those unresponsive to first-line therapies. However, reliable biomarkers for clinical assessment remain elusive.
View Article and Find Full Text PDFGuillain-Barré syndrome.
Nat Rev Dis Primers
December 2024
Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Guillain-Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy. Patients typically develop rapidly progressive weakness and sensory deficits that can result in complete paralysis requiring mechanical ventilation. GBS is usually a monophasic disease in which an aberrant immune response to an infection or other trigger damages the peripheral nerves.
View Article and Find Full Text PDFCoronavirus Disease 2019-Associated Thrombotic Microangiopathy: A Single-Center Experience.
Int J Mol Sci
November 2024
Department of Nephrology, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
Article Synopsis
- COVID-19 can lead to multiorgan issues, including thrombotic microangiopathy (TMA), which we studied in eight patients at our center.
- Most patients showed few COVID-19 symptoms, and TMA occurred after the virus was present in their system; two had additional non-COVID-related factors triggering TMA.
- Treatments varied based on the type of TMA, with some achieving recovery in blood and kidney functions, highlighting the need for tailored treatment approaches due to different causes and responses.
Molecular Hydrogen Therapy in Aneurysmal SAH With RA and Newly-diagnosed SLE, Complicated With Acute Ischemic Infarction: A Case Report of Improved Immune Markers Including Tr1 Cells, Breg Cells and TIM3 Expression on Tc Cells.
In Vivo
October 2024
Rheumatology/Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Article Synopsis
- Most nontraumatic subarachnoid hemorrhages (SAHs) are often caused by ruptured aneurysms, leading to high mortality and serious long-term health issues for survivors.
- A 44-year-old woman with aneurysmal SAH and autoimmune conditions like rheumatoid arthritis and lupus underwent various treatments, including hydrogen therapy, which improved her condition by enhancing immune cell activity.
- This case suggests that molecular hydrogen therapy may provide benefits in treating aneurysmal SAH in patients with autoimmune diseases and indicates a need for more research in this area.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!